Inhibition of DNA-PK may improve response to neoadjuvant chemoradiotherapy in rectal cancer

Cancer Statistics, 2021

(2021) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

(2021) Al B. Benson et al.   Journal of the National Comprehensive Cancer Network

DNA-PK inhibitor peposertib enhances p53-dependent cytotoxicity of DNA double-strand break inducing therapy in acute leukemia

(2021) Eric Haines et al.   Scientific Reports

Pharmacologic Inhibitor of DNA-PK, M3814, Potentiates Radiotherapy and Regresses Human Tumors in Mouse Models

(2020) Frank T. Zenke et al.   MOLECULAR CANCER THERAPEUTICS

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

(2020) Mark T. J. van Bussel et al.   BRITISH JOURNAL OF CANCER

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Therapeutic implications of p53 status on cancer cell fate following exposure to ionizing radiation and the DNA-PK inhibitor M3814

(2019) Qing Sun et al.   MOLECULAR CANCER RESEARCH

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

(2019) Jacqueline H. L. Fok et al.   Nature Communications

Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models

(2019) Hannah C. Wise et al.   Scientific Reports

Cetuximab Combined With Induction Oxaliplatin and Capecitabine, Followed by Neoadjuvant Chemoradiation for Locally Advanced Rectal Cancer: SWOG 0713

(2018) Cynthia Gail Leichman et al.   Clinical Colorectal Cancer

The DNA-PK Inhibitor VX-984 Enhances the Radiosensitivity of Glioblastoma Cells GrownIn Vitroand as Orthotopic Xenografts

(2018) Cindy R. Timme et al.   MOLECULAR CANCER THERAPEUTICS

ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response

(2017) Andrew N. Blackford et al.   MOLECULAR CELL

Predicting the Risk of Bowel-Related Quality-of-Life Impairment After Restorative Resection for Rectal Cancer

(2016) Nick J. Battersby et al.   DISEASES OF THE COLON & RECTUM

Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management

(2015) J. Joshua Smith et al.   BMC CANCER

NSCLC cells demonstrate differential mode of cell death in response to the combined treatment of radiation and a DNA-PKcs inhibitor

(2015) Lan Yu et al.   Oncotarget

Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

(2013) C. G. Engelke et al.   CLINICAL CANCER RESEARCH

Complete Clinical Response After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer: Characterization of Clinical and Endoscopic Findings for Standardization

(2011) Angelita Habr-Gama et al.   DISEASES OF THE COLON & RECTUM

Cetuximab and chemoradiation for rectal cancer–is the water getting muddy?

(2010) Rob Glynne-Jones et al.   ACTA ONCOLOGICA

Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data

(2010) Monique Maas et al.   LANCET ONCOLOGY